Bevacizumab in the treatment of HER2-negative breast cancer

Vito LorussoOncologic Institute, Vito Fazzi Hospital, Lecce, ItalyAbstract: Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Be...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Vito Lorusso
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/63902e14daea4d16883e5a78a2bcb251
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:63902e14daea4d16883e5a78a2bcb251
record_format	dspace
spelling	oai:doaj.org-article:63902e14daea4d16883e5a78a2bcb2512021-12-02T00:22:56ZBevacizumab in the treatment of HER2-negative breast cancer1177-54751177-5491https://doaj.org/article/63902e14daea4d16883e5a78a2bcb2512008-11-01T00:00:00Zhttp://www.dovepress.com/bevacizumab-in-the-treatment-of-her2-negative-breast-cancer-a2633https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Vito LorussoOncologic Institute, Vito Fazzi Hospital, Lecce, ItalyAbstract: Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Bevacizumab is a potent humanized monoclonal antibody to VEGF, which has shown regression of breast cancer in preclinical and clinical setting, either alone or in combination with cytotoxic treatment. Additionally, bevacizumab potentially increases the effectiveness of other anticancer therapies through the normalization of tumor vasculature, reduction of intratumoral pressure and improved tumor oxygenation. Phase 1/2 trials showed significant antitumor effects of bevacizumab in MBC, in particular in tumors not expressing HER2 receptor. A first phase 3 trial in pre-treated MBC patients showed better response rates but no survival benefit from the addition of bevacizumab to capecitabine. However, in two phase 2 trial in first-line setting in patients with MBC, bevacizumab improved progression-free survival in combination with weekly paclitaxel in comparison to paclitaxel alone or in combination with 3-weekly docetaxel in comparison with docetaxel alone, respectively. Bevacizumab in combination with taxanes seems to be a highly effective first-line treatment for MBC patients. Future research will investigate bevacizumab in the neoadjuvant or adjuvant setting, where even more potential may exist for these patients.Keywords: bevacizumab, breast cancer, HER2, HER2-negative breast cancer Vito LorussoDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 813-821 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Vito Lorusso Bevacizumab in the treatment of HER2-negative breast cancer
description	Vito LorussoOncologic Institute, Vito Fazzi Hospital, Lecce, ItalyAbstract: Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Bevacizumab is a potent humanized monoclonal antibody to VEGF, which has shown regression of breast cancer in preclinical and clinical setting, either alone or in combination with cytotoxic treatment. Additionally, bevacizumab potentially increases the effectiveness of other anticancer therapies through the normalization of tumor vasculature, reduction of intratumoral pressure and improved tumor oxygenation. Phase 1/2 trials showed significant antitumor effects of bevacizumab in MBC, in particular in tumors not expressing HER2 receptor. A first phase 3 trial in pre-treated MBC patients showed better response rates but no survival benefit from the addition of bevacizumab to capecitabine. However, in two phase 2 trial in first-line setting in patients with MBC, bevacizumab improved progression-free survival in combination with weekly paclitaxel in comparison to paclitaxel alone or in combination with 3-weekly docetaxel in comparison with docetaxel alone, respectively. Bevacizumab in combination with taxanes seems to be a highly effective first-line treatment for MBC patients. Future research will investigate bevacizumab in the neoadjuvant or adjuvant setting, where even more potential may exist for these patients.Keywords: bevacizumab, breast cancer, HER2, HER2-negative breast cancer
format	article
author	Vito Lorusso
author_facet	Vito Lorusso
author_sort	Vito Lorusso
title	Bevacizumab in the treatment of HER2-negative breast cancer
title_short	Bevacizumab in the treatment of HER2-negative breast cancer
title_full	Bevacizumab in the treatment of HER2-negative breast cancer
title_fullStr	Bevacizumab in the treatment of HER2-negative breast cancer
title_full_unstemmed	Bevacizumab in the treatment of HER2-negative breast cancer
title_sort	bevacizumab in the treatment of her2-negative breast cancer
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/63902e14daea4d16883e5a78a2bcb251
work_keys_str_mv	AT vitolorusso bevacizumabinthetreatmentofher2negativebreastcancer
_version_	1718403803637612544

Bevacizumab in the treatment of HER2-negative breast cancer

Ejemplares similares